+
Site Tour

EuroPCR 2023: Pivotal momentum for tricuspid valve intervention

Fabien Praz chairs this panel discussion on the pivotal momentum for tricuspid valve intervention. He is joined by Christian Besler, Phillipp Lurz, Paul Sorajja and Nina Wunderlich.

Related Videos

EuroPCR 2023: COAPT 5-year follow-up

EuroPCR 2023: Vascular access

EuroPCR 2023: Defining the future

EuroPCR 2023: Mitral regurgitation

AV VALVES 2023: Fast Forward 20 Years

Cruz's testimonial

AV VALVES 2023: TR – Big Gaps

Narcisa's testimonial

TriClip™: Device features

Trending Controversies | AV Valves

AV VALVES 2023: Staged, Concomitant

AV VALVES 2023: Replace, Repair in TR

TRENDING TOPICS

Abbott TMTI sponsored symposium at PCRLV 2024

Unlocking the potential of mitral and tricuspid valves clipping | PCR London Valves 2024

Abbott TMTI at PCRLV - recorded cases and more

RESHAPING the transcatheter treatment of mitral and tricuspid regurgitation | PCR LV '24

Amplatzer™ Amulet™ LAA Occluder

Why Amulet™ LAAO: A Case-Based Review with top experts

A. Shah, D. Shah, O.de Backer

CONNEXT


HUB
RELATED RESOURCES

2-year outcomes from the TRILUMINATE Pivotal trial

ESC 2021: HF & VHD Guidelines

Safety with TriClip TEER

bRIGHT study

CONNEXT


LIVE
RELATED EVENTS

AV VALVES 2023: The Genesis of TEER

EACVI Summit 2023: Congress symposium

AV VALVES 2023: Trending Topics – Timing

AV Valves Summit 2024 | Closing of Day 2

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline